Effect of rimonabant on weight and cardiometabolic risk factors
- PMID: 16896103
- DOI: 10.1001/jama.296.6.649
Effect of rimonabant on weight and cardiometabolic risk factors
Comment on
-
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.JAMA. 2006 Feb 15;295(7):761-75. doi: 10.1001/jama.295.7.761. JAMA. 2006. PMID: 16478899 Clinical Trial.
Similar articles
-
Rimonabant, obesity and diabetes.Prescrire Int. 2007 Jun;16(89):122. Prescrire Int. 2007. PMID: 17585427
-
[Sleep disorders associated with treatment with rimonabant].Rev Neurol. 2008 Oct 16-31;47(8):446. Rev Neurol. 2008. PMID: 18937208 Spanish. No abstract available.
-
[The endocannabinoid system and treatment of obesity].Tidsskr Nor Laegeforen. 2008 Feb 28;128(5):570-1. Tidsskr Nor Laegeforen. 2008. PMID: 18311201 Norwegian.
-
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. J Neuroendocrinol. 2008. PMID: 18426513 Review.
-
An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. J Clin Pharm Ther. 2011. PMID: 21198716 Review.
Cited by
-
Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.BMC Med. 2016 Nov 29;14(1):191. doi: 10.1186/s12916-016-0735-y. BMC Med. 2016. PMID: 27894343 Free PMC article.
-
Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship.PLoS One. 2009;4(3):e5092. doi: 10.1371/journal.pone.0005092. Epub 2009 Mar 31. PLoS One. 2009. PMID: 19333392 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical